Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | OP449 |
Synonyms | |
Therapy Description |
OP449 is an activator of PP2A via inhibition of SET, which may reduce tumor size and block cell proliferation (PMID: 26563471, PMID: 32569675). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
OP449 | PP2A Activator 7 | OP449 is an activator of PP2A via inhibition of SET, which may reduce tumor size and block cell proliferation (PMID: 26563471, PMID: 32569675). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PTEN loss | prostate cancer | sensitive | OP449 | Preclinical | Actionable | In a preclinical study, prostate cancer mouse models deficient for Pten demonstrated inhibition of the PI3K/Akt signaling pathway and a decrease in both tumor size and cell proliferation when treated with OP449 (PMID: 26563471). | 26563471 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|